This Week in Cardiology

This podcast discusses the recent AFib guideline documents, a potential new treatment for POTS, and challenges in treating certain patient populations. It highlights the findings and limitations of trials on ablation and left atrial appendage occlusion. The speaker raises concerns about a preventive procedure and introduces a small study on transcutaneous vagus nerve stimulation for POTS with promising results.

Cardiology expert, Dr. John Mandrola, discusses various topics including SGLT2 inhibitors for post-MI patients, blood transfusion strategies in acute MI, Factor XI inhibitors in AF, and FDA approval of a renal denervation device. The podcast provides insights into the latest research, trial outcomes, and implications for clinical practice.

Dr. John Mandrola reviews the SELECT, ORBITA2, and ARTESIA trials in this week's podcast. Topics include the potential of semaglutide in reducing CVD risk, the significance of the Orbita II trial in interventional cardiology, and the management of subclinical A-fib with anticoagulation therapy.

Topics discussed in this podcast include renal denervation for hypertension, the risk of deadly decisions in the emergency department, FDA approval of Tirzepatide for obesity treatment, and a preview of major trials at the American Heart Association conference.

Topics discussed include tricuspid regurgitation therapy, left atrial appendage trials, reflections on being too soft on medical science, and questioning the scientific process in cardiology.

The podcast covers topics such as the Million Hearts RCT, ENRICH AF, TAVI vs SAVR, Partner 3 and Evolut-low-risk trials, and myocardial viability. It explores the impact of risk calculators and risk reduction payments on patient treatment motivation. The Million Heart Study suggests that extra treatment may lead to reduced cardiovascular events but more hospitalizations. Clinical trials comparing E-doxaban and Tavi versus SAVR reveal varying outcomes and concerns about death rates, stroke rates, and rehospitalization. A study compares treatment options for ischemic cardiomyopathy and discusses the role of viability testing.

In this week's podcast, topics include listener feedback, oral anticoagulation in patients with intracranial hemorrhage, the difference between statistical and clinical significance, and the correlation between statins and diabetes. The hosts also discuss intravascular imaging in cardiology procedures, the use of anticoagulation in intracranial hemorrhage, and the measurement of 10-year risk scores in cardiovascular disease prevention. They also explore a study challenging the commonly used P-value threshold for significance in medical research.

This week's podcast covers GLP-1 agonists, imaging during PCI, and the power of sham controls in procedure trials. Topics include positive results in the FLOW trial, the use of Semaglutide in HFpEF, adverse effects of GLP-1 agonists, and the need for updates in intravascular imaging guidelines. Ablation of the right greater splanktic nerve in HF and the importance of sham controls in research are also discussed.

In this podcast, they discuss topics such as the benefits of coated vs uncoated aspirin, a new trial in coronary artery disease, conflicts of interest in medical device coverage determinations, the role of primary care physicians in decoding atrial fibrillation recurrence, and the impact of stricter hypertension criteria on CHADSVASC scoring.

Reader feedback, leadless pacing, ABIM, SGLT2 inhibitors, peri-operative MI after cardiac surgery, and. AHA late-breakers are the topics John Mandrola, MD, covers in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Reader Feedback Sep 22, 2023 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/996694 - ODYSSEY OUTCOMES trial https://www.nejm.org/doi/full/10.1056/nejmoa1801174 - FOURIER https://www.nejm.org/doi/full/10.1056/nejmoa1615664 II. Leadless Pacing - Leadless vs Transvenous Pacemaker Study https://doi.org/10.1093/europace/euad269 III. ABIM News Heart Societies Ready to Split From ABIM Over Long-Standing MOC Disputes https://www.medscape.com/viewarticle/996747 IV. SGLT2 inhibitors Empagliflozin Gets FDA Nod for CKD Without T2D or HF https://www.medscape.com/viewarticle/996873 - EMPA-Kidney https://www.nejm.org/doi/full/10.1056/NEJMoa2204233 V. Peri-Op MI after Cardiac Surgery Cardiac Troponin Predicts Mortality Post Surgery https://www.medscape.com/viewarticle/996877 - Austrian Perioperative MI study https://doi.org/10.1016/j.jacc.2023.07.011 - Vision https://www.nejm.org/doi/10.1056/NEJMoa2000803 VI. AHA Late Breakers - Link to Late-Breakers https://professional.heart.org/en/meetings/scientific-sessions/programming/late-breaking-science#late-breaking You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net